Alpha Profiles · Company Profile

Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.

https://registry.alpha.ac/companies/definium-therapeutics-inc

Entity: Public listing published
Primary listing: NASDAQ: DFTX
Verification: Partially verified
Last reviewed: 2026-09-06T05:19:31.871297+00:00

Overview

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is i

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Brandi L. Roberts

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-182034Apr 27, 2026

Daniel Karlin

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-182034Apr 27, 2026

Mark R. Sullivan

Chief Legal Officer and Corporate Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-182034Apr 27, 2026

Matthew T. Wiley

Chief Commercial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-182034Apr 27, 2026

Robert Barrow

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-182034Apr 27, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 6, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.